Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe
Author:
Funder
Astellas Pharma US
Roche Diagnostics
Ipsen Biopharmaceuticals
AstraZeneca
Exelixis
Bayer Fund
Novartis
Bristol-Myers Squibb
Pfizer
Eisai Incorporated
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference15 articles.
1. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019
2. NCCN guidelines insights: kidney cancer, version 2.2020;Motzer;J Natl Compr Canc Netw,2019
3. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma;Albiges;Eur Urol,2019
4. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial;Choueiri;Ann Oncol,2020
5. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma;Albiges;Ann Oncol,2020
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities;Current Oncology Reports;2023-04-20
2. Treatment strategies for clear cell renal cell carcinoma: Past, present and future;Frontiers in Oncology;2023-03-21
3. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials;European Journal of Cancer;2021-09
4. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma;Expert Opinion on Pharmacotherapy;2021-08-18
5. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis;Immunotherapy;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3